• Race and TargImmune to develop new cancer therapies pharmaceutical-technology
    July 12, 2017
    Australian-based specialist pharmaceutical firm Race Oncology has executed a Letter of Intent (LoI) with Swiss-based biotechnology TargImmune Therapeutics to enter a joint venture (JV) between the two companies to develop new and improved cancer therapies
PharmaSources Customer Service